The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Multiple myeloma highlights at ASH 2020
Jesus Berdeja, MD, Sarah Cannon Center for Blood Cancers, Nashville, TN, highlights the exciting updates in multiple myeloma presented at ASH 2020, focusing on the advances in bispecific antibody therapies including products targeting BCMA, GPRC5D and FcRH5. These agents have yielded encouraging response rates and show impressive safety profiles. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
